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Abstract
Background: Lactate dehydrogenase-elevating virus (LDV) is a natural infectious agent of mice. Like several other viruses,
LDV causes widespread and very rapid but transient activation of both B cells and T cells in lymphoid tissues and the blood.
The mechanism of this activation has not been fully described and is the focus of the current studies.
Principal Findings: A known inducer of early lymphocyte activation is IFNa, a cytokine strongly induced by LDV infection.
Neutralization of IFNa in the plasma from infected mice ablated its ability to activate lymphocytes in vitro. Since the primary
source of virus-induced IFNa in vivo is often plasmacytoid dendritic cells (pDC’s), we depleted these cells prior to LDV infection
and tested for lymphocyte activation. Depletion of pDC’s in vivo eradicated both the LDV-induced IFNa response and
lymphocyte activation. A primaryreceptorinpDC’s for single strandedRNAvirusessuch as LDVis the toll-like receptor7 (TLR7)
pattern recognition receptor. Infection of TLR7-knockout mice revealed that both the IFNa response and lymphocyte
activation were dependent on TLR7 signaling in vivo. Interestingly, virus levels in both TLR7 knockout mice and pDC-depleted
mice were indistinguishable from controls indicating that LDV is largely resistant to the systemic IFNa response.
Conclusion: Results indicate that LDV-induced activation of lymphocytes is due to recognition of LDV nucleic acid by TLR7
pattern recognition receptors in pDC’s that respond with a lymphocyte-inducing IFNa response.
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Introduction
Lactate dehydrogenase-elevating virus (LDV) is a small, positive
sense, single stranded RNA virus of the Arteriviridae family,
related to coronaviruses such as the severe acute respiratory
syndrome (SARS) virus [1,2,3,4]. It is a natural infectious agent of
mice that causes very rapid lytic infections generally restricted to a
minor subset of non-essential macrophages involved in scavenging
extracellular lactate dehydrogenase [5,6]. The rapid loss of this
subset results in the elevated lactate dehydrogenase levels for
which the virus is named [7]. Virus titers peak within the first day
of infection as susceptible target cells are depleted, and then the
infection is maintained at a much lower chronic level dependent
on the replenishment of new macrophage targets [8]. LDV
establishes chronic infections regardless of mouse strain, age, sex
or immune-status [5,8,9,10]. No clinical signs are typically
associated with LDV infections, although co-infection with
retroviruses can lead to CNS disease under certain circumstances
[11,12], and mice infected with LDV have suppressed immune
responses [13,14,15,16]. We recently found that acute infection
with LDV induced a state of partial and transient activation in the
vast majority of splenic lymphocytes. Activation was characterized
by high surface expression of the very early activation marker
CD69 [16]. CD69 is the first surface marker known to be
upregulated during the activation of lymphocytes and has recently
been shown to interact with S1P1 to inhibit the egress of
lymphocytes from lymphoid tissues [17]. CD69 expression is
upregulated by T cell receptor (TCR) ligation [18] but is not
dependent upon it and can be induced by inflammatory cytokines
such as IFNa [19,20].
Results
To investigate the mechanism of lymphocyte activation
following LDV infection we first analyzed the kinetics of CD69
upregulation on splenic lymphocytes at several time points
following infection. CD69 expression was analyzed by flow
cytometry as previously described [16] and became detectable at
14 hours post-infection, peaked at 16 to 24 hours, and returned
almost to background levels by 72 hours (Figure 1A). The
induction of CD69 occurred on CD4+ and CD8+ T cells, as
well as B cells (Figure 1B). In addition to the spleen, CD69
upregulation was also observed, albeit to a lesser extent, on
lymphocytes from the blood, lymph nodes, and bone marrow
(Figure 1C). In contrast, no significant upregulation was observed
on lymphocytes from the thymus, which are primarily immature T
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which is upregulated later in the activation cascade and is typically
dependent on TCR ligation [21], did not increase in expression
during the first day of LDV infection (data not shown). This result
is consistent with partial rather than full activation of the
lymphocytes.
The rapid systemic appearance of CD69 expression suggested
that a soluble factor such as IFNa, a known early responder to
viral infections [22] and strong trigger of CD69 expression
[17,19,20], was inducing the response. To determine whether the
LDV-induced IFNa response [16] could be responsible for CD69
induction, we first utilized the fact that IFNa induces CD69
expression on B cells in vitro [19]. Splenic B cells were isolated from
naı ¨ve mice using CD19+ magnetic beads (Miltenyi Biotec) and
cultured with 10% plasma taken from mice infected 16 hours
earlier with LDV. B cells cultured for 4 hours with plasma from
infected, but not uninfected mice, significantly upregulated CD69
expression (Figure 2). Furthermore, upregulation of CD69
expression was prevented by addition of a neutralizing antibody
specific for IFNa (PBL Interferon Source) in a concentration-
dependent manner. These findings suggested that the IFNa
response to LDV infection might be responsible for the partial
activation of lymphocytes in vivo as well.
Although any cell can produce IFNa in response to infection,
the acute systemic response to viruses has been attributed to
production by plasmacytoid dendritic cells (pDC’s, also known as
interferon-producing cells or IPC) [23,24,25], which comprise only
a minor subpopulation of cells but can produce 1000 times as
much IFNa as other cells [24]. Conventional DC’s can also
produce high amounts of IFNa if they are directly infected, but
pDC’s are uniquely able to secrete high levels of IFNa in response
to endocytosed antigen. The role of pDC’s in production of IFNa
during LDV infection was investigated by depleting mice of pDC’s
the day before LDV infection using a pDC-specific depleting
antibody [26]. The plasma IFNa response at 16 hours post-
infection with LDV, as measured by ELISA, was abolished by
pDC depletion (Figure 3A). Thus the systemic IFNa response was
predominantly due to production by pDC’s. In addition to loss of
the IFNa response in pDC-depleted mice, we also observed the
failure of splenic lymphocytes to upregulate CD69. A histogram
showing CD69 expression on splenocytes from a representative
mouse is shown in Figure 3B. Combined with the dependence on
IFNafor upregulation of CD69 on B cells in vitro, the data indicate
Figure 1. LDV-induced upregulation of CD69. Cells were stained
and analyzed by flow cytometry as described (22). (A) Kinetics showing
the percentage of splenic lymphocytes with CD69 upregulation.
Significant upregulation (P,.05) was observed between 12 and 48hpi
(n=224 mice per group per time point). (B) Upregulation of CD69 on
major splenic lymphocyte subsets at 16hpi with LDV was analyzed by
co-staining with antibodies for CD69 and either CD4, CD8 or CD19 as
indicated. The difference in percentage of CD69
hi cells between naı ¨ve
and infected mice was statistically significant for all subsets by t test,
P=0.0225 for CD4
+ T cells, 0.003 for CD8
+ T cells, and 0.0018 for CD19
+
B cells (n=2 mice per naı ¨ve group and 3 mice per infected group.) (C)
Tissue distribution of CD69 upregulation. Lymphocytes from spleen,
blood, lymph nodes, bone marrow, and thymus were examined at
16hpi with LDV. All tissues except the thymus showed a significantly
higher percentage of CD69
hi lymphocytes when infected with LDV
infected (P,0.01 for all groups indicated by *).
doi:10.1371/journal.pone.0006105.g001
Figure 2. CD69 upregulation in B cells blocked by anti-IFNa
antibody. The addition of 10% serum from LDV-infected mice
harvested at 16hpi induced upregulation of CD69 in a significant
percentage of splenic B cells (2610
5 B cells/well) cultured in vitro for 4
hours following their isolation with CD19 magnetic beads (Miltenyi
Biotec). Addition of 2 or 20 ml of anti-IFNa antibody (PBL Interferon
Source) to 198 or 180 ml cultures respectively, significantly reduced the
percentage of cells with CD69 upregulation (P#0.0001 by t test).
doi:10.1371/journal.pone.0006105.g002
LDV Induced IFNa Responses
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the systemic IFNa response to LDV infection. Interestingly, the
loss of the IFNa response in pDC-depleted mice produced no
statistically significant difference in LDV plasma levels as
measured by real time PCR (15) (Figure 3C). Since IFNa can
act in both autocrine and paracrine manners to limit virus
replication and spread [27], it appears that LDV is quite resistant
to the antiviral effects of IFNa, even when present at very high
systemic levels.
Given that LDV is a single-stranded RNA virus, we investigated
whether the pDC-dependent IFNa response was mediated by toll
like receptor 7 (TLR7), which is highly expressed by pDC’s, binds
to single stranded viral RNA, and is capable of initiating IFNa
responses in pDC’s without their direct infection [28]. Mice
containing a genetically inactivated TLR7 gene [29,30] failed to
mount IFNa responses or to upregulate CD69 expression in
response to LDV infection, whereas genetically matched TLR7
wild type mice showed strong IFNa responses and CD69
upregulation (Figure 4A, B). Consistent with the results from
pDC depletions, LDV plasma titers were again not significantly
different in the absence of TLR7 expression and IFNa production
(Figure 4C). These results are similar to data from type I interferon
receptor-deficient mice infected with LDV, although that study
noted slight (two fold) increases in virus titers in the absence of type
I interferon signaling [31].
Discussion
Together, our data indicate that pDC’s activated in a TLR7-
dependent manner are primarily responsible for the rapid systemic
IFNa response following infection of mice with LDV. Further-
more, the interferon response was most likely responsible for the
transient expression of the CD69 very early activation marker on
lymphocytes during acute LDV infection. IFNa–dependent,
partial activation of lymphocytes has also been reported during
acute infection with Semliki forest virus [20], human adenovirus 2,
West Nile virus, and A/WSN influenza virus [32] in mice.
However, not all acute viral infections induce partial activation, as
it does not occur in Friend retrovirus infections of mice [16]. Such
broad activation is by definition non-specific, and leaves open the
question of how it benefits the host. Alsharifi et al. have proposed
that IFNa-induced partial activation may promote adaptive
immune responses by lowering the threshold for full activation
once antigen-specific recognition occurs [33]. If so, IFNa may be a
very important regulatory link between the innate and adaptive
immune responses. Based on the findings that CD69 acts
downstream of IFNa to inhibit lymphocyte egress from lymphoid
organs [17], it is also likely that CD69 expression facilitates
sustained contacts between lymphocytes and antigen presenting
cells during inflammatory responses, thereby enhancing full
activation of antigen-specific lymphocytes.
Figure 3. In vivo depletion of plasmacytoid dendritic cells
abolishes IFNa production. Naı ¨ve (A.BY x B10)F1 mice were
depleted of pDC’s by injection of 0.5 mg mPDCA-1 antibody (Miltenyi
Biotec) 24 h prior to infection with LDV, and blood samples were
collected at 16hpi. (A) Interferon alpha levels in naı ¨ve mice (left), LDV-
infected normal mice (middle), and LDV-infected, pDC-depleted mice
(right) were measured by ELISA (PBL Interferon Source). The difference
between the two LDV-infected groups was statistically significant by t
test (P,0.0001, n=5). (B) Flow cytometric analysis of peripheral blood
lymphocytes showed significant reductions in LDV-induced expression
of CD69 in pDC depleted mice (average mean fluorescence intensity of
114.3+/214.25 vs. 42.96+/211.85, n=5, p=0.0049 by t test). A
representative histogram of CD69 expression on cells from LDV-
infected mice that were pDC-depleted pDC
2) or mock-treated (pDC
+)i s
shown. The histograms of cells from naı ¨ve animals overlapped with the
curves from pDC depleted mice (data not shown). (C) pDC depletion
did not significantly alter LDV levels in plasma as indicated by results
from semiquantitative real-time RT-PCR as previously described [16].
Relative LDV levels are indicated by real time PCR critical threshold (Ct)
values, which were not significantly different between LDV-infected
normal mice (pDC
+) Ct=22.05+/20.33, and LDV-infected, pDC-depleted
mice (pDC
2) Ct=21.72+/20.43 (n=5).
doi:10.1371/journal.pone.0006105.g003
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Figure 4. LDV-induced CD69 upregulation is TLR7-dependent.
TLR7 wild type and knockout mice on the 129SvEv genetic background
were infected with LDV and blood was analyzed at 16hpi. (A) IFNa
levels in plasma were significantly reduced in TLR7
2/2 mice as
measured by ELISA (PBL Interferon Source). Values in TLR7
+/+ mice
averaged 795.5 pg/ml while only trace amounts of IFNa were detected
in TLR7
2/2 mice ( TLR7
+/+ vs. TLR7
2/2 p=0.0041 by T test). (B) The low
levels of IFNa in TLR7
2/2 mice correlated with reduced percentages of
lymphocytes expressing CD69 (TLR7
+/+ 57.30%+/24.15% CD69
+ vs.
TLR7
2/2 4.37%+/20.28% CD69
+, n=3, p=0.0002 by t test). (C) LDV-
specific semiquantitative real-time RT-PCR as previously described [16]
revealed no significant difference in virus levels between TLR7 knockout
and TLR7 wild type mice as measured by critical threshold values
(TLR7
+/+ Ct=25.93+/20.59 vs. TLR7
2/2 26.90+/20.38, n=3 mice/
group).
doi:10.1371/journal.pone.0006105.g004
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